R&D channel feed – Endpoints News

R&D channel feed

Novo reports 'really powerful' cardio, death risk reduction for semaglutide in kidney disease

11 months ago

Zealand touts safety of new ‘double-G’ drug despite modest weight loss in small trial

11 months ago

J&J plans for capped, flexible dosing after four patient deaths in early study of actinium prostate cancer drug

11 months ago

Merck, Kelun trumpet Phase 3 breast cancer data for anti-TROP2 ADC

11 months ago

After $4B Takeda deal, Nimbus lays out ‘grand’ hopes for its next-gen immunotherapy drug

11 months ago

Pfizer shares the ADC data that convinced it to start a Phase 3 lung cancer trial

11 months ago

Nuvation Bio shares pivotal China data for cancer drug from AnHeart buyout

11 months ago

ASCO abstracts are out, with data for ADCs, Nimbus' next-gen I/O drug and more

11 months ago

UK biotech revives former Kyowa Kirin cancer drug for Epstein-Barr-driven diseases

11 months ago

AstraZeneca taps more China-derived tech with $19M cancer deal for Nona antibodies

11 months ago

Crinetics' stock jumps following promising Ph2 data in four patients with rare genetic disorder

11 months ago

Otsuka terminates Alzheimer's agitation drug after failed Phase 3

11 months ago

Daiichi Sankyo to open two new research sites in Cambridge and Munich this year

11 months ago

Oral drug shows promise in diabetic macular edema as biotech touts anti-VEGF injection alternative

11 months ago

NIH drafts policy on ensuring access to new drugs funded by taxpayers

11 months ago

AstraZeneca counts on ‘difficult-to-copy’ therapies for big 2030 goal and beyond

11 months ago

Sanofi, OpenAI, Formation Bio announce AI drug development partnership

11 months ago

FDA lifts partial clinical hold on Larimar’s Friedreich’s ataxia treatment

11 months ago

GSK says long-acting asthma treatment clears two Phase 3 studies

11 months ago

UK biotech raises £35M to develop solid tumor drugs based on machine learning

11 months ago

Dyne Therapeutics sharpens case for two muscle disease therapies with updated data

11 months ago

AstraZeneca, Amgen tout Phase 2a Tezspire data in COPD ahead of Dupixent decision

11 months ago

Gilead's rare liver disease drug improves symptoms in another Phase 3 study ahead of FDA decision

12 months ago

FDA rejects liver cancer drug combo, shares of Korean biotech tank

12 months ago

First page Previous page 41 42 434445 46 47 Next page Last page